Skip to main content
. 2022 Sep 9;13:5313. doi: 10.1038/s41467-022-32960-3

Fig. 1. Trial profile and clinical response in r/r MM patients treated with CAR-T cell infusion.

Fig. 1

a Patient enrollment. b Anti–BCMA single-chain variable fragment (scFv), a hinge and transmembrane regions, and 4-1BB costimulatory moiety, and CD3ζ T-cell activation domain. c Blood and fecal sample collection. d Clinical response; CRS grade distribution in 43 r/r MM patients. e Numbers of BCMA CAR-T cell percentages in PB assessed by FACS in different therapy stages after CAR-T cell infusion and serum concentrations of IL-10 and IFN-γ in different therapy stages among the CR (n = 24 biologically independent patients), VGPR (n = 6 biologically independent patients), and PR (n = 11 biologically independent patients) groups. Blue, green, and red colors indicate CR, VGPR, and PR group, respectively. Data are presented as mean values ± SEM. Significance determined by two-sided Kruskal-Wallis test and adjustments were made for multiple comparison. P values for CAR-T percent in PB, serum IL-10 and IFN-γ between CR and PR groups in CRSb stage were 0.004, 0.048, 0.085, respectively. *p < 0.05, **p < 0.01. f Body temperature and serum concentrations of IL-6 and IFN-γ in different therapy stages among CRS grade groups. (Grade 1 CRS group: n = 8 biologically independent patients, Grade 2 CRS group: n = 16 biologically independent patients, and Grade 3 CRS group: n = 19 biologically independent patients). Data are presented as mean values ± SEM. Significance determined by two-sided Kruskal-Wallis test and adjustments were made for multiple comparison. P values for serum IL-6 and IFN-γ between Grade 1 CRS and Grade 3 CRS were 0.002 and 0.006, respectively. *p < 0.05, **p < 0.01. g Representative MM patients with impressive antimyeloma response. Positron emission tomography-computed tomography scans before and 5 months after CAR-T cell treatment showing complete elimination of large number of MM bone metastases. Before receiving CAR-T cell infusion, 43.5% of bone marrow cells of the patient were plasma cells, but after 1.5 months of infusion, dramatic eradication of MM from the bone marrow was observed; and MM cells became undetectable by flow cytometry. The bar indicates a length of 5 μm.